Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of βIII-Tubulin Expression as a Predictive Marker

BACKGROUND. This randomized phase II trial was designed to compare the rate of pathologic complete response (pCR) induced by neoadjuvant cyclophosphamide plus doxorubicin (AC) followed by ixabepilone or paclitaxel in women with early stage breast cancer (BC). Expression of βIII-tubulin as a predicti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Saura, Cristina, Tseng, Ling-Ming, Chan, Stephen, Chacko, Raju T., Campone, Mario, Manikhas, Alexy, Nag, Shona M., Leichman, Cynthia G., Dasappa, Lokanatha, Fasching, Peter A., Hurtado de Mendoza, Fernando, Symmans, W. Fraser, Liu, David, Mukhopadhyay, Pralay, Horak, Christine, Xing, Guan, Pusztai, Lajos
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2013
Matèries:
Academia-Pharma Intersect: Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3720631/
https://ncbi.nlm.nih.gov/pubmed/23853246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0075
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars